Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuki Nishikawa

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Respiratory Medicine|April 23, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapyHirotomo Machiyama, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Thoracic Cancer|June 3, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective StudyKeijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
JTO Clinical and Research Reports|October 27, 2025
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLCKensuke Kanaoka, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancerKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Respiratory Medicine|April 23, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapyHirotomo Machiyama, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Thoracic Cancer|June 3, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective StudyKeijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
JTO Clinical and Research Reports|October 27, 2025
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLCKensuke Kanaoka, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancerKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
Pageof 4